Displaying drugs 326 - 331 of 331 in total
Saprisartan
Saprisartan is an AT1 receptor antagonist. It is based on medications of losartan's prototypical chemical structure. The mode of (functional) AT1 receptor antagonism has been characterized as insurmountable/noncompetitive for saprisartan. It is very likely that slow dissociation kinetics from the AT1 receptor underlie insurmountable antagonism .
Experimental
Faldaprevir
Faldaprevir has been investigated for the treatment of Chronic Hepatitis C.
Investigational
Olcegepant
Boehringer Ingelheim Pharmaceuticals’ olcegepant (BIBN 4096) is a selective Calcitonin Gene-Related Peptide (CGRP) antagonist, a new class of drugs in development for the treatment of acute migraine attacks. Olcegepant is undergoing phase II trials in Europe and the US, with preliminary results suggesting that CGRP antagonists may represent a potential...
Investigational
CoA-S-acetyl 5-bromotryptamine
Experimental
Displaying drugs 326 - 331 of 331 in total